tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Nov 11;9(11):1313.
doi: 10.3390/vaccines9111313.
First Report of Two Cases of Löfgren's Syndrome after SARS-CoV-2 Vaccination-Coincidence or Causality?
Jan-Gerd Rademacher[SUP] 1 [/SUP], Björn Tampe[SUP] 1 [/SUP], Peter Korsten[SUP] 1 [/SUP]
Affiliations
Abstract
Sarcoidosis can present as an acute form or take a chronic course. One of the acute presentations is Löfgren's syndrome (LS), consisting of the symptom triad of bilateral hilar lymphadenopathy, erythema nodosum, and ankle periarthritis. In addition, there are occasional reports of sarcoid-like reactions following drug exposures. Nevertheless, reports of sarcoidosis or LS after vaccination have not been published. Here, we report two cases of de novo LS in a temporal association with different vaccines against the new coronavirus SARS-CoV-2. One patient developed the first symptoms three days after the second vaccination (first vaccination ChadOx-1, Astra Zeneca; second vaccination CX-024414, Moderna); in the second patient, symptoms started 28 days after the first vaccination (ChadOx-1, Astra Zeneca). Both patients eventually required treatment with glucocorticoids. Both patients achieved clinical improvement with treatment. In conclusion, we report the first two cases of LS shortly after SARS-CoV-2 vaccination.
Keywords: COVID-19; Löfgren’s syndrome; SARS-CoV-2; sarcoidosis; vaccination.
. 2021 Nov 11;9(11):1313.
doi: 10.3390/vaccines9111313.
First Report of Two Cases of Löfgren's Syndrome after SARS-CoV-2 Vaccination-Coincidence or Causality?
Jan-Gerd Rademacher[SUP] 1 [/SUP], Björn Tampe[SUP] 1 [/SUP], Peter Korsten[SUP] 1 [/SUP]
Affiliations
- PMID: 34835244
- DOI: 10.3390/vaccines9111313
Abstract
Sarcoidosis can present as an acute form or take a chronic course. One of the acute presentations is Löfgren's syndrome (LS), consisting of the symptom triad of bilateral hilar lymphadenopathy, erythema nodosum, and ankle periarthritis. In addition, there are occasional reports of sarcoid-like reactions following drug exposures. Nevertheless, reports of sarcoidosis or LS after vaccination have not been published. Here, we report two cases of de novo LS in a temporal association with different vaccines against the new coronavirus SARS-CoV-2. One patient developed the first symptoms three days after the second vaccination (first vaccination ChadOx-1, Astra Zeneca; second vaccination CX-024414, Moderna); in the second patient, symptoms started 28 days after the first vaccination (ChadOx-1, Astra Zeneca). Both patients eventually required treatment with glucocorticoids. Both patients achieved clinical improvement with treatment. In conclusion, we report the first two cases of LS shortly after SARS-CoV-2 vaccination.
Keywords: COVID-19; Löfgren’s syndrome; SARS-CoV-2; sarcoidosis; vaccination.